US Patent

US9150579 — Selective PI3K delta inhibitors

Composition of Matter · Assigned to Rhizen Pharmaceuticals AG · Expires 2033-07-02 · 7y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects selective inhibitors of PI3K delta protein kinases, including the compound UMBRALISIB TOSYLATE, and methods for preparing and using them.

USPTO Abstract

The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: US9150579
Jurisdiction: US
Classification: Composition of Matter
Expires: 2033-07-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.